Overview
Servier Polska is a pharmaceutical company that focuses on three therapeutic areas: cardiometabolism, oncology, and neurology. It has developed worasydenib, a targeted molecular therapy for patients with grade 2 glioma with IDH gene mutations. The company employs 20,000 people and treats 100 million patients daily with its original medications.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 1998-04-01. Active
12 1840 0007 2210 0000 0819 0110
40 1030 1508 0000 0008 2206 3000- 63 1840 0007 2210 0000 0810 1019
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
8 tenders recorded as contractor: 2 national ($62,440) and 6 EU ($6,984,495).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Aug 6, 2026 | Dostawa produktów leczniczych i wyrobów medycznych, opatrunków specjalistycznych, asortymentu ostatnio wprowadzonego do Receptariusza oraz leków stosowanych w programach lekowych – uzupełnienie | $224.5K$224,470 | Wojewódzki Szpital Podkarpacki Im. Jana Pawła II w Krośnie | |
| Apr 3, 2026 | Dostawa produktów leczniczych dla SP ZOZ w Łęcznej | $3.5M$3,509,524 | Samodzielny Publiczny Zakład Opieki Zdrowotnej w Łęcznej | |
| Jan 19, 2026 | Dostawę leków stosowanych w programach lekowych oraz wybranych produktów leczniczych i materiałów opatrunkowych – Doszacowanie | $77,547$77,547 | Wojewódzki Szpital Podkarpacki Im. Jana Pawła II w Krośnie |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
Each member of the management board has the right to represent the company individually.
Ownership
| Owner | Share value | Stake |
|---|---|---|
Biofarma S.a.s. | $5,657,549.97 | 100% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Olivier Jacques, Gerard Laureau (69)  | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Fresenius Medical Care Sscsp. z o.o. | $23,515,709.38 | freseniusmedicalcare.com | ||
| Adamed Technologysp. z o.o. | $8,360,772.47 | adamedtechnology.com | ||
| Wilandt BrothersS.A. | $5,868,648.33 | wilandt.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-07-16 | PKD change (Removed: 46.18.Z, 63.99.Z, 72.19.Z, 73.1, 74.90.Z; Added: 18.1, 58.19.Z, 59.11.Z, 63.92.Z, 70.20.Z, 71.20.C, 72.10.Z, 73.20.Z, 85.69.Z, 86.9) | |
| 2022-11-21 | Address change (Jana Kazimierza 10, 01-248, Warszawa → Ul. Burakowska 14, 01-066, Warszawa) | |
| 2017-05-30 | PKD change (Removed: 18.1, 18.20.Z, 58.11.Z, 58.19.Z, 59.11.Z, 59.12.Z, 59.20.Z, 70.2, 71.19.Z, 71.20, 73.20.Z, 77.40.Z, 85.5, 85.60.Z, 86.9; Added: 72.19.Z) | |
| 2010-09-17 | PKD change (Removed: 22.11.Z, 22.2, 22.3, 51.18.Z, 73.10.F, 74.13, 74.14.A, 74.30.Z, 74.40.Z, 74.8, 80.42, 85.14, 92.1, 93.05; Added: 18.1, 18.20.Z, 46.18.Z, 58.11.Z, 58.19.Z, 59.11.Z, 59.12.Z, 59.20.Z, 63.99.Z, 70.2, 71.19.Z, 71.20, 73.1, 73.20.Z, 74.90.Z, 77.40.Z, 85.5, 85.60.Z, 86.9) | |
| 2005-07-20 | Address change (Sienna 75, 00-833, Warszawa → Jana Kazimierza 10, 01-248, Warszawa) |
FAQ
Last updated: 2026-03-25